289 related articles for article (PubMed ID: 27231799)
1. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
[TBL] [Abstract][Full Text] [Related]
2. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
[TBL] [Abstract][Full Text] [Related]
4. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
5. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
[TBL] [Abstract][Full Text] [Related]
7. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
8. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
9. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
11. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
[TBL] [Abstract][Full Text] [Related]
12. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
[TBL] [Abstract][Full Text] [Related]
17. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Dranitsaris G; Schmitz S; Broom RJ
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
[TBL] [Abstract][Full Text] [Related]
18. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]